Relay Therapeutics
RLAY
189 hedge funds and large institutions have $1.1B invested in Relay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 51 reducing their positions, and 19 closing their positions.
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
41% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 51
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
7% more funds holding
Funds holding: 177 → 189 (+12)
2.95% less ownership
Funds ownership: 103.82% → 100.86% (-3%)
22% less capital invested
Capital invested by funds: $1.41B → $1.1B (-$310M)
38% less call options, than puts
Call options by funds: $61K | Put options by funds: $98K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$36.5M |
| 2 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$24.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$43.7M |
| 2 |
JP Morgan Chase
New York
|
-$22.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.6M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$8.97M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$7.42M |
RLAY Hedge Fund Activity: Q1 2024 in Review
189 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q1 2024, worth a combined $1.1B — down 22% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RLAY positions and 19 closed out — a net gain of 12 holders — while 72 added to existing stakes and 51 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $36.5M. The largest seller was BVF Inc, exiting entirely with an estimated $43.7M sold.
- 189 institutional investors held Relay Therapeutics (RLAY) as of Q1 2024, up from 177 in Q4 2023.
- Funds reported $1.1B of Relay Therapeutics stock for Q1 2024, down 22% quarter-over-quarter.
- 31 funds opened new Relay Therapeutics positions in Q1 2024 and 19 closed out, a net change of +12 holders.
- The largest Relay Therapeutics buyer in Q1 2024 was Braidwell, an estimated $36.5M added.
- The largest Relay Therapeutics seller in Q1 2024 was BVF Inc, an estimated $43.7M sold.
Based on aggregated 13F filings for Q1 2024.